{"schema_version":"secwatch.filing_event.v1","accession":"0001585364-24-000066","form_type":"8-K","ticker":"PRGO","cik":"0001585364","company_name":"PERRIGO Co plc","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.093631+00:00","generated_at":"2026-06-02T18:29:03.287345+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Perrigo Reports Q1 2024 Adjusted EPS of $0.29, Above Projection; Net Sales Down 8.4%","bullets":["Q1 net sales $1.1B, down 8.4% vs prior year; organic net sales declined 7.0% due to infant formula and SKU prioritization actions.","Adjusted diluted EPS of $0.29, $0.06 ahead of projection primarily from infant formula shipment timing; down from $0.45 YoY.","Reaffirms FY2024 outlook: organic sales growth 1%-3%, adjusted EPS range $2.50-$2.65, interest expense ~$180M.","Infant formula impacted adjusted gross margin by -280 bps and adjusted EPS by -$0.30 in the quarter.","Svend Andersen, EVP & President CSCI, to retire; Roberto Khoury appointed as successor effective August 1, 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001585364-24-000066","json":"https://secwatch.observer/filing/0001585364-24-000066.json","markdown":"https://secwatch.observer/filing/0001585364-24-000066.md","text":"https://secwatch.observer/filing/0001585364-24-000066.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585364/000158536424000066/0001585364-24-000066-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585364/000158536424000066/prgo-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T18:29:03.287345+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1f972128385311068cf7cccf9f3d68cbbeaa756a","claim":"PERRIGO Co plc reported first quarter ended March 30, 2024 results: revenue $1.1 billion, EPS $0.03. Guidance reaffirmed.","evidence_excerpt":"Business Recently Announced Plan to Divest HRA Rare Diseases Business; Expects to Redeploy Proceeds for Debt Paydown First Quarter 2024 Highlights: • First quarter net sales of $1.1 billion declined 8.4% versus the prior year quarter. First quarter organic 1 net sales decreased 7.0%, due primarily to 1) -4.3 percentage points impact due to lower net sales in infant","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585364/000158536424000066/0001585364-24-000066-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 30, 2024"},{"label":"Revenue","value":"$1.1 billion"},{"label":"EPS","value":"$0.03"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}